Reduced levels of catalase activity potentiate MPP+-induced toxicity: Comparison between MN9D cells and CHO cells

Toxicology Letters

Volumn 104, Issue 1-2, 1999, Pages 49-56

  Hussain, Saber ^a   Hass, Bruce S ^b   Slikker Jr , William ^a   Ali, Syed F ^a,c  

^a National Centre   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Antioxidant; Catalase; CHO cells; MN9D cells; MPP+; MPTP; Neurotoxicity

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMITROLE; CATALASE;

ANIMAL CELL; ARTICLE; CELL LINE; CELL SURVIVAL; CHO CELL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; ENZYME ACTIVITY; NERVE CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

1-METHYL-4-PHENYLPYRIDINIUM; AMITROLE; ANIMALS; ANTIOXIDANTS; CATALASE; CELL DIVISION; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; CHO CELLS; CRICETINAE; HUMANS; NEURONS;

MAMMALIA;

EID: 0032949370     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(98)00231-8     Document Type: Article

References (36)

1. +induced oxygen radical formation with mitochondrial enzymes. Free Rad. Biol. Med. 15:1993;181-186.
2. Aebi, H., 1984. Catalase in vitro. In: Packer, L. (Ed), Methods in Enzymology. Vol 105. Academic Press, NY, pp. 121-126.
3. Ali S.F., David S.N., Newport G.D., Cadet J.L., Slikker W. Jr. MPTP-induced oxidative stress and neurotoxicity are age-dependent:evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse. 18:1994;27-34.
4. Cadet J.L., Ali S.F., Rothman R.B., Epstein C.J. Neurotoxicity, drugs and abuse, and the Cu, Zn-superoxide dismutase transgenic mice. [Review]. Molec. Neurobiol. 11:1995;155-163.
5. 2-resistant CHO cell variants: I-Relationship between catalase activity and the induction/stability of the oxidant-resistant phenotypes. Biochem. Pharmacol. 45:1993;2251-2257.
6. Chan P., DeLanney L.E., Irwin I., Langston J.W., DiMonte D. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem. 57:1991;348-351.
7. +, a metabolite of MPTP, brain synaptosomes. Biochem. Biophys. Res. Commun. 128:1985;1228-1232.
8. Choi H.K., Won L.A., Kontur P.J., Hammond D.N., Fox A.P., Wainer B.H., Haffmann P.C., Heller A. Immortalization of embryonic mesencephalic dopaminergic neurons by somatic cell fusion. Brain Res. 552:1991;67-76.
9. +-induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport. Brain Res. 715:1996;1-8.
10. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., Marsden C.D. Increased nigral iron content in postmortem Parkinsonian brain. Lancet. 2:1987;1219-1220.
11. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836.
12. Ebadi M., Srinivasan S.K., Baxi M.D. Oxidative stress and antioxidant therapy in Parkinson's disease. Progress in Neurobiol. 48:1986;1-19.
13. +. Brain Res. 735:1996;42-49.
14. Gotz M.E., Freyberger A., Riederer P. Oxidative stress: a role in the pathogenesis of Parkinson's disease [Review]. J. Neural Transmission. Suppl. 29:1990;241-249.
15. Harris E.D. Regulation of antioxidant enzymes. FASEB J. 6(9):1992;2675-2683.
16. +) in the pathogenesis of Parkinson's disease. Brain Res. 575:1992;285-298.
17. +) within catecholaminergic neurons. Neurotoxicology. 12:1992;285-302.
18. Jones D.P., Thor H., Andersson B., Orrenius S. Detoxification reactions in isolated hepatocytes. Role of glutathione peroxidase, catalase, and formaldehyde dehydrogenase in reactions relating to N-demethylation by the cytochrome P-450 system. J. Biol. Chem. 253:1987;6031-6037.
19. Kang Y.J., Chen Y., Epstein P.N. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J. Biol. Chem. 271:1986;12610-12616.
20. Lai M., Griffiths H., Pall H., Williams A., Lunec J. An investigation into the role of reactive oxygen species in the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity using neuronal cell lines. Biochem. Pharmacol. 45:1993;927-933.
21. Langston J.W. MPTP and Parkinson's disease. Trends Neurosci. 8:1985;79-83.
22. Liu Y., Roghani A., Edwards R.H. Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. Proc. Natl. Acad. Sci. (USA). 89:1992;9074-9078.
23. McCrodden J.M., Tipton K.F., Sullivan J.P. The neurotoxicity of MPTP and relevance to Parkinson's disease. Pharmacol. Toxicol. 67:1990;8-13.
24. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Letts. 33:1982;305-310.
25. Perry T.L., Yong V.W., Clavier R.M., Jones K., Wright J.M., Foulks J.G., Wall R.A. Partial protection from the dopaminergic neurotoxin N-methyl- 4-phenyl- 1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Letts. 60:1985;109-114.
26. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-induced neurotoxicity. J. Neurosci. 12:1992;1658-1667.
27. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B.H. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brain. J. Neurochem. 52:1989;515-520.
28. Rossetti Z.L., Sotgiu A., Sharp D.E., Hadjiconstantinou M., Neff N.H. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem. Pharmacol. 37:1988;4573-4574.
29. Sandler M., Glover V., Clow A., Jarman J. Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase? [Review]. Adv. Neurol. 60:1993;238-241.
30. Schapira A.H. MPTP and other Parkinson-inducing agents [Review]. Curr. Opin. Neurol. Neurosurg. 5:1992;396-400.
31. Snyder S.H, D'Amato R.J. MPTP: a neurotoxin relevant to the patho-physiology of Parkinson's disease. Neurology. 36:1986;250-258.
32. Tang L., Todd R., Heller A., O'Malley L. Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblasts and dopaminergic cell lines. J. Pharmacol. Exp. Ther. 268:1994;495-502.
33. Tetrud J.W., Langston J.W. Protective and preventive therapeutic strategies: monoamine oxidase inhibitors [Review]. Neurologic Clinics. 10:1992;541-552.
34. Thiffault C., Aumont N., Quirion R., Poirier J. Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J. Neurochem. 65:1995;2725-2733.
35. Williams A., Waring R. The MPTP tale: pathway to prevention of Parkinson's disease? [Review]. Brit. J. Hosp. Med. 49:1993;716-719.
36. Zang L.Y., Misra H.P. Generation of reactive oxygen species during the monoamine oxidase-catalyzed oxidation of the neurotoxicant, 1-methyl- 4-phenyl- 1,2,3,6- tetrahydropyridine. J. Biol. Chem. 268:1993;16504-16512.